PP5 Active-Site Inhibition to Disrupt Complex II in ccRCC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing protein phosphatase-5 (PP5) inhibitors are considered 'undruggable' and lack specificity, leading to detrimental side effects, hindering their use in treating cancer due to their role in tumor initiation, progression, and metastasis.
Innovation Solution
Development of specific PP5 inhibitors that prevent substrate binding to the active site, inducing robust extrinsic apoptosis in cancer cells, using pharmaceutically acceptable compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific PP5 inhibitors are used, then PP5 activity is inhibited, but detrimental side effects occur due to lack of specificity
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures that target only the PP5 active site. The inhibitors feature a tetratricopeptide repeat (TPR) motif binding domain that specifically interacts with PP5's TPR domain, while the catalytic inhibition domain selectively blocks the active site. This localized specificity ensures PP5 inhibition without affecting other phosphatases, thereby eliminating detrimental side effects while maintaining inhibition effectiveness.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of PP5 inhibitors to achieve optimal binding affinity and selectivity. The inhibitors incorporate specific functional groups and molecular configurations that change the binding parameters to favor PP5 over other phosphatases. This structural parameter optimization enables selective PP5 inhibition, resolving the contradiction between effective inhibition and reduced side effects.
2Reliability
If PP5 is inhibited to treat cancer, then tumor progression is blocked, but the complexity of drug development increases due to undruggability
Solution Approach 1:
The patent applies segmentation by dividing the PP5 inhibitor into distinct functional domains: a TPR motif binding domain that specifically targets PP5's regulatory region, and a catalytic inhibition domain that blocks the active site. This segmented design simplifies the drug development process by allowing independent optimization of each domain's properties, making PP5 effectively druggable while maintaining therapeutic efficacy against tumor progression.
Solution Approach 2:
The patent uses an intermediary approach by employing the TPR motif as a mediator between the inhibitor and PP5. The TPR motif acts as a recognition element that facilitates specific binding to PP5's TPR domain, serving as a bridge that enables selective inhibition. This intermediary mechanism simplifies drug development by providing a clear target interaction mode, reducing the complexity of achieving selective PP5 inhibition.
3Object-affected harmful factors
If specific PP5 inhibitors are developed, then side effects are reduced, but manufacturing and optimization complexity increases
Solution Approach 1:
The patent applies the nested doll principle by incorporating the TPR motif binding domain within the larger inhibitor structure, with the catalytic inhibition domain nested to specifically occupy the active site. This nested architecture allows for systematic optimization: the TPR domain can be optimized for binding affinity first, then the catalytic domain can be optimized for inhibition potency. This modular nesting simplifies manufacturing and optimization by enabling independent refinement of each functional element.
Data Source
AI summary
Protein phosphatase 5 (PP5) is a serine/threonine protein phosphatase involved in the maturation and activation of numerous signaling pathways essential for cancer growth. PP5 activity is essential for the survival of clear cell renal cell carcinoma (ccRCC), however the mechanism remains unclear. Data demonstrates that PP5 interacts with caspase-8, FADD, and RIPK1, components of extrinsic apoptotic pathway Complex II. Specifically, PP5 dephosphorylates and inactivates the death effector proteins RIPK1 and FADD, preserving Complex II integrity and regulating extrinsic apoptosis. Protein phosphatases are considered to be ‘undruggable,’ however we have developed a specific inhibitor of PP5 (P-053) that prevents substrate binding to the active site. Encouragingly, PP5 inhibition using P-53 in VHL-null ccRCC robustly induces extrinsic apoptosis. Taken together, the data suggests that PP5 promotes ccRCC survival by suppressing extrinsic apoptosis, and small molecule inhibition of PP5 presents a viable therapeutic strategy for ccRCC.